Video Experimental Relacionado
Updated: Apr 3, 2026

Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes
Published on: December 16, 2022
La política de la FDA y la medicina cardiovascular
Joseph S Ross1, Aaron S Kesselheim2
1From Section of General Internal Medicine and the Robert Wood Johnson Foundation Clinical Scholars Program, Yale University School of Medicine; Department of Health Policy and Management, Yale University School of Public Health; and Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, CT (J.S.R.); and Program On Regulation, Therapeutics, And Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (A.S.K.). joseph.ross@yale.edu.
No abstract available in PubMed .
Videos de Conceptos Relacionados
Cardiovascular Drugs: Classification based on Therapeutic Indications
FDA Approved Drugs: Changes to Approved Drugs
Drug Regulation
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Atherosclerosis III: Management
Heart Failure V: Medical Management

